ALK and non-small cell lung carcinoma: Moreover, the second endpoint of our study was to determine whether an ALK-rearrangement could be detected in CTCs enriched by NanoVelcro assay from ALK-positive advanced NSCLC patients, facilitating treatment strategy design and prognosis monitoring.